Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

PET-Derived Quantitative Metrics for Response and Prognosis in Lymphoma.

Kostakoglu L, Chauvie S.

PET Clin. 2019 Jul;14(3):317-329. doi: 10.1016/j.cpet.2019.03.002. Review.

PMID:
31084772
2.

End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma.

Kostakoglu L, Nowakowski GS.

PET Clin. 2019 Jul;14(3):307-315. doi: 10.1016/j.cpet.2019.03.001. Review.

PMID:
31084771
3.

Quantitative comparison of pre-therapy 99mTc-macroaggregated albumin SPECT/CT and post-therapy PET/MR studies of patients who have received intra-arterial radioembolization therapy with 90Y microspheres.

Knešaurek K, Tuli A, Pasik SD, Heiba S, Kostakoglu L.

Eur J Radiol. 2018 Dec;109:57-61. doi: 10.1016/j.ejrad.2018.10.015. Epub 2018 Oct 21.

PMID:
30527312
4.

Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma.

Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, Kostakoglu L, Serafini AN, Pampaloni MH, Jensen J, Armor T, Lin T, White T, Stambler N, Apfel S, DiPippo VA, Mahmood S, Wong V, Jimenez C.

J Nucl Med. 2019 May;60(5):623-630. doi: 10.2967/jnumed.118.217463. Epub 2018 Oct 5.

5.

The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.

Andriole GL, Kostakoglu L, Chau A, Duan F, Mahmood U, Mankoff DA, Schuster DM, Siegel BA; LOCATE Study Group.

J Urol. 2019 Feb;201(2):322-331. doi: 10.1016/j.juro.2018.08.050.

7.

Updating the role of FDG PET/CT for evaluation of lung cancer manifesting in nonsolid nodules.

Liu Y, Yankelevitz DF, Kostakoglu L, Beasley MB, Htwe Y, Salvatore MM, Yip R, Henschke CI.

Clin Imaging. 2018 Nov - Dec;52:157-162. doi: 10.1016/j.clinimag.2018.07.004. Epub 2018 Jul 6.

PMID:
30096553
8.

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.

Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schöder H, Popplewell LL, Chang JE, Moskowitz CH, Wagner-Johnston N, Leonard JP, Friedberg JW, Kahl BS, Cheson BD, Bartlett NL.

Blood. 2018 Sep 6;132(10):1013-1021. doi: 10.1182/blood-2018-01-827246. Epub 2018 Jul 26.

9.

Feasibility and diagnostic performance of hybrid PET/MRI compared with PET/CT for gynecological malignancies: a prospective pilot study.

Schwartz M, Gavane SC, Bou-Ayache J, Kolev V, Zakashansky K, Prasad-Hayes M, Taouli B, Chuang L, Kostakoglu L.

Abdom Radiol (NY). 2018 Dec;43(12):3462-3467. doi: 10.1007/s00261-018-1665-2.

PMID:
29948057
10.

ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy.

Ratai EM, Zhang Z, Fink J, Muzi M, Hanna L, Greco E, Richards T, Kim D, Andronesi OC, Mintz A, Kostakoglu L, Prah M, Ellingson B, Schmainda K, Sorensen G, Barboriak D, Mankoff D, Gerstner ER; ACRIN 6684 trial group.

PLoS One. 2018 Jun 14;13(6):e0198548. doi: 10.1371/journal.pone.0198548. eCollection 2018.

11.

Surveillance Imaging in HPV-related Oropharyngeal Cancer.

Su W, Miles BA, Posner M, Som P, Kostakoglu L, Gupta V, Bakst RL.

Anticancer Res. 2018 Mar;38(3):1525-1529.

PMID:
29491081
12.

Comparison of Standardized Uptake Value Ratio Calculations in Amyloid Positron Emission Tomography Brain Imaging.

Knešaurek K, Warnock G, Kostakoglu L, Burger C; for Alzheimer's Disease Neouroimaging Initiative*.

World J Nucl Med. 2018 Jan-Mar;17(1):21-26. doi: 10.4103/wjnm.WJNM_5_17.

13.

Metabolic Tumor Volume Metrics in Lymphoma.

Kostakoglu L, Chauvie S.

Semin Nucl Med. 2018 Jan;48(1):50-66. doi: 10.1053/j.semnuclmed.2017.09.005. Review.

PMID:
29195618
14.

Guest Editorial.

Kostakoglu L.

Semin Nucl Med. 2018 Jan;48(1):2-3. doi: 10.1053/j.semnuclmed.2017.10.001. Epub 2017 Oct 27. No abstract available.

PMID:
29195614
15.

Reply: Fact Sheet About Interim and End-of-Treatment 18F-FDG PET/CT in Lymphoma.

Kostakoglu L.

J Nucl Med. 2017 Jul;58(7):1179. doi: 10.2967/jnumed.117.190512. Epub 2017 Apr 6. No abstract available.

16.

Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using 18F-Fluciclovine PET/CT.

Miller MP, Kostakoglu L, Pryma D, Yu JQ, Chau A, Perlman E, Clarke B, Rosen D, Ward P.

J Nucl Med. 2017 Oct;58(10):1596-1602. doi: 10.2967/jnumed.116.188375. Epub 2017 Apr 6.

17.

Metabolic Tumor Volume: We Still Need a Platinum-Standard Metric.

Gallamini A, Kostakoglu L.

J Nucl Med. 2017 Feb;58(2):196-197. doi: 10.2967/jnumed.116.184663. Epub 2016 Nov 10. No abstract available.

18.
19.

FDG-PET for Early Response Assessment in Lymphomas: Part 1-Hodgkin Lymphoma.

Cheson BD, Kostakoglu L.

Oncology (Williston Park). 2017 Jan 15;31(1):45-9. Review.

20.

General Biomarker Recommendations for Lymphoma.

Rimsza L, Fedoriw Y, Staudt LM, Melnick A, Gascoyne R, Crump M, Baizer L, Fu K, Hsi E, Chan JW, McShane L, Leonard JP, Kahl BS, Little RF, Friedberg JW, Kostakoglu L.

J Natl Cancer Inst. 2016 Dec 16;108(12). pii: djw250. Print 2016 Dec.

21.

The ideal dual-isotope imaging combination in evaluating patients with suspected infection of pelvic pressure ulcers.

Heiba SI, Stempler L, Sullivan T, Kolker D, Kostakoglu L.

Nucl Med Commun. 2017 Feb;38(2):129-134. doi: 10.1097/MNM.0000000000000625.

PMID:
27977535
22.

Response Assessment Criteria and Their Applications in Lymphoma: Part 2.

Moghbel MC, Mittra E, Gallamini A, Niederkohr R, Chen DL, Zukotynski K, Nadel H, Kostakoglu L.

J Nucl Med. 2017 Jan;58(1):13-22. doi: 10.2967/jnumed.116.184242. Epub 2016 Nov 22. Review.

23.

Cerebral [18 F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy.

Dickstein DL, Pullman MY, Fernandez C, Short JA, Kostakoglu L, Knesaurek K, Soleimani L, Jordan BD, Gordon WA, Dams-O'Connor K, Delman BN, Wong E, Tang CY, DeKosky ST, Stone JR, Cantu RC, Sano M, Hof PR, Gandy S.

Transl Psychiatry. 2016 Sep 27;6(9):e900. doi: 10.1038/tp.2016.175.

24.

Optimization of yttrium-90 PET for simultaneous PET/MR imaging: A phantom study.

Eldib M, Oesingmann N, Faul DD, Kostakoglu L, Knešaurek K, Fayad ZA.

Med Phys. 2016 Aug;43(8):4768. doi: 10.1118/1.4958958.

PMID:
27487894
25.

FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study.

Kostakoglu L, Goy A, Martinelli G, Caballero D, Crump M, Gaidano G, Baetz T, Buckstein R, Fine G, Fingerle-Rowson G, Berge C, Sahin D, Press O, Sehn L.

Leuk Lymphoma. 2017 Feb;58(2):372-381. Epub 2016 Jun 24.

PMID:
27339738
26.

ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI.

Gerstner ER, Zhang Z, Fink JR, Muzi M, Hanna L, Greco E, Prah M, Schmainda KM, Mintz A, Kostakoglu L, Eikman EA, Ellingson BM, Ratai EM, Sorensen AG, Barboriak DP, Mankoff DA; ACRIN 6684 Trial Group.

Clin Cancer Res. 2016 Oct 15;22(20):5079-5086. Epub 2016 May 16.

27.

Response Assessment Criteria and Their Applications in Lymphoma: Part 1.

Moghbel MC, Kostakoglu L, Zukotynski K, Chen DL, Nadel H, Niederkohr R, Mittra E.

J Nucl Med. 2016 Jun;57(6):928-35. doi: 10.2967/jnumed.115.166280. Epub 2016 Apr 28. Review.

28.

The evolving role of response-adapted PET imaging in Hodgkin lymphoma.

Coyle M, Kostakoglu L, Evens AM.

Ther Adv Hematol. 2016 Apr;7(2):108-25. doi: 10.1177/2040620715625615. Review.

29.

Lymph nodes can accurately be measured on PET-CT for lymphoma staging/restaging without a concomitant contrast enhanced CT scan.

Simpson WL Jr, Lee KM, Sosa N, Cooper N, Scigliano E, Brody JD, Doucette JT, Kostakoglu L.

Leuk Lymphoma. 2016 May;57(5):1083-93. doi: 10.3109/10428194.2015.1089437. Epub 2015 Nov 16.

PMID:
26422408
30.

A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.

Kostakoglu L, Duan F, Idowu MO, Jolles PR, Bear HD, Muzi M, Cormack J, Muzi JP, Pryma DA, Specht JM, Hovanessian-Larsen L, Miliziano J, Mallett S, Shields AF, Mankoff DA; ACRIN 668 Investigative Team.

J Nucl Med. 2015 Nov;56(11):1681-9. doi: 10.2967/jnumed.115.160663. Epub 2015 Sep 10.

31.

Reply to G. Keramida et al.

Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller S, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD.

J Clin Oncol. 2015 Dec 1;33(34):4121-2. doi: 10.1200/JCO.2015.63.2125. Epub 2015 Aug 24. No abstract available.

PMID:
26304890
32.

Does interim PET increase the value of ABVD in advanced-stage Hodgkin lymphoma?

Gallamini A, Kostakoglu L.

Ann Oncol. 2015 Jun;26(6):1045-7. doi: 10.1093/annonc/mdv160. No abstract available.

33.

Direct comparison of neck pinhole dual-tracer and dual-phase MIBI accuracies with and without SPECT/CT for parathyroid adenoma detection and localization.

Heiba SI, Jiang M, Rivera J, Genden E, Inabnet W 3rd, Machac J, Kostakoglu L.

Clin Nucl Med. 2015 Jun;40(6):476-82. doi: 10.1097/RLU.0000000000000778.

PMID:
25783516
34.

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.

Evens AM, Kostakoglu L.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):135-43. doi: 10.1182/asheducation-2014.1.135. Epub 2014 Nov 18. Review. Erratum in: Hematology Am Soc Hematol Educ Program. 2015;2015:652.

PMID:
25696846
35.

Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al.

Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller S, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cavalli F, Lister TA, Cheson BD.

J Clin Oncol. 2015 Apr 1;33(10):1221-3. doi: 10.1200/JCO.2014.59.9373. Epub 2015 Feb 17. No abstract available.

PMID:
25691678
36.

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.

Evens AM, Kostakoglu L.

Blood. 2014 Nov 27;124(23):3356-64. doi: 10.1182/blood-2014-05-577627. Review. Erratum in: Blood. 2015 Apr 9;125(15):2450.

37.

(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.

Mylam KJ, Kostakoglu L, Hutchings M, Coleman M, Lamonica D, Czuczman MS, Diehl LF, Nielsen AL, Jensen P, Loft A, Hendel HW, Iyer V, Leppä S, Jyrkkiö S, Holte H, Eriksson M, Gillstrøm D, Hansen PB, Seppänen M, Hjorthaug K, Brown Pde N, Pedersen LM.

Leuk Lymphoma. 2015 Jul;56(7):2005-12. doi: 10.3109/10428194.2014.975800. Epub 2014 Nov 20.

PMID:
25330442
38.

State of the art imaging of multiple myeloma: comparative review of FDG PET/CT imaging in various clinical settings.

Mesguich C, Fardanesh R, Tanenbaum L, Chari A, Jagannath S, Kostakoglu L.

Eur J Radiol. 2014 Dec;83(12):2203-2223. doi: 10.1016/j.ejrad.2014.09.012. Epub 2014 Sep 28. Review.

PMID:
25308249
39.

The Mount Sinai clinical pathway for the management of pheochromocytoma.

Galati SJ, Said M, Gospin R, Babic N, Brown K, Geer EB, Kostakoglu L, Krakoff LR, Leibowitz AB, Mehta L, Muller S, Owen RP, Pertsemlidis DS, Wilck E, Xiao GQ, Levine AC, Inabnet WB 3rd.

Endocr Pract. 2015 Apr;21(4):368-82. doi: 10.4158/EP14036.RA. Epub 2014 Oct 8. Review.

PMID:
25297659
40.

Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury.

Mitsis EM, Riggio S, Kostakoglu L, Dickstein DL, Machac J, Delman B, Goldstein M, Jennings D, D'Antonio E, Martin J, Naidich TP, Aloysi A, Fernandez C, Seibyl J, DeKosky ST, Elder GA, Marek K, Gordon W, Hof PR, Sano M, Gandy S.

Transl Psychiatry. 2014 Sep 16;4:e441. doi: 10.1038/tp.2014.91.

41.

Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD.

J Clin Oncol. 2014 Sep 20;32(27):3048-58. Erratum in: J Clin Oncol. 2016 Jul 20;34(21):2562.

42.

In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.

Hutchings M, Kostakoglu L, Zaucha JM, Malkowski B, Biggi A, Danielewicz I, Loft A, Specht L, Lamonica D, Czuczman MS, Nanni C, Zinzani PL, Diehl L, Stern R, Coleman M.

J Clin Oncol. 2014 Sep 1;32(25):2705-11. doi: 10.1200/JCO.2013.53.2838. Epub 2014 Jul 28.

PMID:
25071108
43.

FDG-PET imaging for Hodgkin lymphoma: current use and future applications.

Kostakoglu L, Evens AM.

Clin Adv Hematol Oncol. 2014 Jan;12(1):20-35. Review.

PMID:
25000313
44.

The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.

Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, Meignan M, Mikhaeel GN, Loft A, Zaucha JM, Seymour JF, Hofman MS, Rigacci L, Pulsoni A, Coleman M, Dann EJ, Trentin L, Casasnovas O, Rusconi C, Brice P, Bolis S, Viviani S, Salvi F, Luminari S, Hutchings M.

Haematologica. 2014 Jun;99(6):1107-13. doi: 10.3324/haematol.2013.103218. Epub 2014 Mar 21.

45.

Current role of FDG PET/CT in lymphoma.

Kostakoglu L, Cheson BD.

Eur J Nucl Med Mol Imaging. 2014 May;41(5):1004-27. doi: 10.1007/s00259-013-2686-2. Epub 2014 Feb 12. Review.

PMID:
24519556
46.

A consecutive case series experience with [18 F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition.

Mitsis EM, Bender HA, Kostakoglu L, Machac J, Martin J, Woehr JL, Sewell MC, Aloysi A, Goldstein MA, Li C, Sano M, Gandy S.

Mol Neurodegener. 2014 Feb 3;9:10. doi: 10.1186/1750-1326-9-10.

47.

Radiographic extracapsular extension and treatment outcomes in locally advanced oropharyngeal carcinoma.

Kann BH, Buckstein M, Carpenter TJ, Bakst R, Misiukiewicz K, Genden E, Posner M, Kostakoglu L, Som P, Gupta V.

Head Neck. 2014 Dec;36(12):1689-94. doi: 10.1002/hed.23512. Epub 2014 Jan 13.

PMID:
24123603
48.

Early detection of recurrent disease by FDG-PET/CT leads to management changes in patients with squamous cell cancer of the head and neck.

Kostakoglu L, Fardanesh R, Posner M, Som P, Rao S, Park E, Doucette J, Stein EG, Gupta V, Misiukiewicz K, Genden E.

Oncologist. 2013;18(10):1108-17. doi: 10.1634/theoncologist.2013-0068. Epub 2013 Sep 13.

49.

State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response".

Kostakoglu L, Cheson BD.

Front Oncol. 2013 Sep 4;3:212. doi: 10.3389/fonc.2013.00212. Review.

50.

A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.

Grant BW, Jung SH, Johnson JL, Kostakoglu L, Hsi E, Byrd JC, Jones J, Leonard JP, Martin SE, Cheson BD.

Cancer. 2013 Nov 1;119(21):3797-804. doi: 10.1002/cncr.28299. Epub 2013 Aug 6.

Supplemental Content

Loading ...
Support Center